Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension;Transición de prostaciclina intravenosa a subcutánea en la hipertensión pulmonar

Revista Espanola de Cardiologia

Volumn 56, Issue 8, 2003, Pages 818-821

  Escribano Subías, Pilar ^a   Cea Calvo, Luis ^a   Tello de Menesses, Rocío ^a   Gómez Sánchez, Miguel A ^a   Delgado Jiménez, Juan F ^a   Sáenz de la Calzada, Carlos ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Prostacyclin; Pulmonary hypertension; Treprostinil

Indexed keywords

PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; UNIPROST; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE;

ABSCESS; ADULT; ARTICLE; CASE REPORT; CATHETER INFECTION; CENTRAL VENOUS CATHETER; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; IMPLANTATION; INFUSION SYSTEM; PULMONARY HYPERTENSION; QUALITY OF LIFE; SEPSIS; STAPHYLOCOCCUS INFECTION; SURVIVAL; BACTERIAL INFECTION; CENTRAL VENOUS CATHETERIZATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIHYPERTENSIVE AGENTS; BACTERIAL INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED;

EID: 0141669255     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050337     Document Type: Article

References (9)

1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
2. McLaughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation 2002;106:1477-82.
3. Badesch BD, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum disease. A randomized, controlled trial. Ann Intern Med 2000;132: 425-34.
4. Rosenzweig EB, Kernstein D, Barst JR. Long-term prostacyclin for pulmonary hypertension with associated congenital defects. Circulation 1999;99:1858-65.
5. Rich S, editor. Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998. Evian, France. September 6-10, 1998. Co-sponsored by the World Health Organization. Disponible en: www.who.int/ncd/cvd/pph.htm
6. Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:800-4.
7. Olschewski H, Simmoneau G, Galié N, Higenbottam T, Naejie R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
8. Escribano P, Lázaro M, Tello R, Delgado JF, Cea-Calvo L, Velázquez T, et al. Dos años de experiencia con treprostinil (análogo estable de la prostaciclina) en infusión subcutánea continua en el tratamiento de la hipertensión pulmonar severa [resumen]. Rev Esp Cardiol 2002;55(Supl 2):22.
9. Vachiéry JL, Hill N, Zwicke D, Barst R, Blackburn S, Naejie R. Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002;121:1561-5.